Y Intercept Hong Kong Ltd Makes New $4.81 Million Investment in Perrigo Company plc $PRGO

Y Intercept Hong Kong Ltd bought a new stake in Perrigo Company plc (NYSE:PRGO) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 447,451 shares of the company’s stock, valued at approximately $4,806,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Geneos Wealth Management Inc. lifted its stake in Perrigo by 439.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after purchasing an additional 786 shares in the last quarter. Kestra Investment Management LLC grew its position in shares of Perrigo by 57.1% in the second quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock valued at $47,000 after purchasing an additional 642 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Perrigo by 116.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after purchasing an additional 1,014 shares during the last quarter. UMB Bank n.a. increased its holdings in shares of Perrigo by 161.5% in the fourth quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock valued at $27,000 after purchasing an additional 1,213 shares during the last quarter. Finally, Meeder Asset Management Inc. purchased a new position in Perrigo during the fourth quarter worth approximately $28,000. 95.91% of the stock is currently owned by institutional investors and hedge funds.

Perrigo Trading Down 0.1%

Shares of PRGO stock opened at $11.01 on Monday. Perrigo Company plc has a 1-year low of $9.23 and a 1-year high of $28.43. The firm has a market cap of $1.52 billion, a PE ratio of -0.84, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. The company has a 50-day moving average of $10.89 and a two-hundred day moving average of $12.11. The company has a debt-to-equity ratio of 1.45, a current ratio of 2.72 and a quick ratio of 1.59.

Perrigo (NYSE:PRGO) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The business had revenue of $841.80 million for the quarter, compared to the consensus estimate of $1.04 billion. Perrigo had a negative net margin of 43.50% and a positive return on equity of 9.96%. The business’s revenue was down 7.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.60 EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, analysts predict that Perrigo Company plc will post 2.11 EPS for the current year.

Perrigo Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Friday, May 29th were paid a $0.29 dividend. The ex-dividend date of this dividend was Friday, May 29th. This represents a $1.16 dividend on an annualized basis and a dividend yield of 10.5%. Perrigo’s payout ratio is presently -8.85%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on PRGO shares. Zacks Research raised Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Weiss Ratings upgraded Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. One research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $19.33.

Perrigo Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.